Mavrilimumab: an evidence based review of its potential in the treatment of rheumatoid arthritis
Manuela Di Franco, Maria Chiara Gerardi, Bruno Lucchino, Fabrizio Conti Reumatologia, Dipartimento di Medicina Interna e Specialità Mediche, Sapienza Università di Roma, Rome, Italy Abstract: Rheumatoid arthritis (RA) management has greatly improved with the development of biologic disease modifying antirheumatic drugs, but a proportion of patients do not improve despite the biologic drugs currently available. We need new biologic agents with novel mechanisms of action for the treatment of refractory patients. Recent evidence has shown that granulocyte-macrophage colony-stimulating factor (GM-CSF) is involve...
Source: Core Evidence - March 11, 2014 Category: Drugs & Pharmacology Tags: Core Evidence Source Type: research
A clinical review of micafungin
de la Torre P, Reboli AC (Source: Core Evidence)
Source: Core Evidence - February 25, 2014 Category: Drugs & Pharmacology Source Type: research
Micafungin: an evidence-based review of its place in therapy
Pola de la Torre,1 Annette C Reboli1 1Cooper Medical School of Rowan University, Camden, NJ, USA Abstract: Invasive fungal infections have increased throughout the world. Many of these infections occur in patients with multiple comorbidities who are receiving medications with the potential for interactions with antifungal therapy that could lead to renal and hepatic dysfunction. The second marketed echinocandin, micafungin, was approved in 2005 for the treatment of esophageal candidiasis and prophylaxis of invasive Candida infections in patients undergoing hematopoietic stem cell transplantation. The indication for use wa...
Source: Core Evidence - February 24, 2014 Category: Drugs & Pharmacology Tags: Core Evidence Source Type: research
Ceftazidime avibactam for Gram negative infections
Lagacé-Wiens P, Walkty A, Karlowsky JA (Source: Core Evidence)
Source: Core Evidence - January 24, 2014 Category: Drugs & Pharmacology Source Type: research
Ceftazidime & ndash;avibactam: an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections
(Source: Core Evidence)
Source: Core Evidence - January 23, 2014 Category: Drugs & Pharmacology Tags: Core Evidence Source Type: research
Ceftazidime–avibactam: an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections
Philippe Lagacé-Wiens,1,2 Andrew Walkty,1,2 James A Karlowsky1,2 1Clinical Microbiology, Diagnostic Services Manitoba, 2Department of Medical Microbiology and Infectious Diseases, Faculty of Medicine, University of Manitoba, Winnipeg, MB, Canada Abstract: Avibactam (NXL104, AVE1330A) is a semi-synthetic, non-β-lactam, β-lactamase inhibitor that is active against Ambler class A, class C, and some class D serine β-lactamases. In this review, we summarize the in vitro data, pharmacology, mechanisms of action and resistance, and clinical trial data relating to the use of this agent combined with ceftazid...
Source: Core Evidence - January 23, 2014 Category: Drugs & Pharmacology Tags: Core Evidence Source Type: research
Targeted therapy in triple-negative metastatic breast cancer
Clark O, Botrel TE, Paladini L, Ferreira MB (Source: Core Evidence)
Source: Core Evidence - January 5, 2014 Category: Drugs & Pharmacology Source Type: research
Targeted therapy in triple-negative metastatic breast cancer: a systematic review and meta-analysis
Conclusion: Targeted therapy, when associated with conventional CT, demonstrated gains in the PFS of patients with TNBC.Keywords: triple-negative, chemotherapy, breast cancer, systematic review (Source: Core Evidence)
Source: Core Evidence - January 5, 2014 Category: Drugs & Pharmacology Tags: Core Evidence Source Type: research
Lapatinib with or without CET in HER-2-positive breast cancer
Botrel TE, Paladini L, Clark OA (Source: Core Evidence)
Source: Core Evidence - September 30, 2013 Category: Drugs & Pharmacology Source Type: research
Sugammadex as a reversal agent for neuromuscular block
Schaller SJ, Fink H (Source: Core Evidence)
Source: Core Evidence - September 24, 2013 Category: Drugs & Pharmacology Source Type: research
